New treatments for adult T-cell leukemia/lymphoma Review
| Authors: | Epstein-Peterson, Z. D.; Gurumurthi, A.; Horwitz, S. M. |
| Review Title: | New treatments for adult T-cell leukemia/lymphoma |
| Abstract: | Adult T cell leukemia lymphoma (ATL) is a mature T cell neoplasm caused by human T-cell lymphotropic virus type 1 (HTLV-1). ATL is endemic in specific geographic regions of the world closely related to areas with high prevalence of HLTV-1 infection, including Southwestern Japan, the Caribbean Basin, Central Africa, South America, Northern and Central Australia. HLTV-1 is primarily transmitted through breastmilk in asymptomatic carriers with a long latency period before transformation into ATL in 3 – 5 % of carriers after acquisition of multiple leukemogenic mutations. The Shimoyama classification established by the Japanese Lymphoma Study Group more than three decades ago remains clinically relevant and practical for guiding treatment. Due to the rarity of this illness, prospective, large prospective clinical are challenging to perform and treatment recommendations are based upon limited evidence. Aggressive disease subtypes have median survival ranging in months and the only curative therapy remains achieving deep remission with induction therapy followed by consolidative allogeneic transplantation. The prognosis for relapsed disease remains dismal due to chemo-refractoriness and limited therapeutic options. Herein, we review the current landscape of novel therapeutic agents with a focus on relapsed and refractory ATL including their mechanisms of action, resistance, and clinical efficacy. © 2025 |
| Keywords: | cancer survival; unclassified drug; overall survival; fludarabine; histone deacetylase inhibitor; lenalidomide; prednisone; neutropenia; doxorubicin; interferon; drug dose reduction; drug efficacy; drug safety; drug withdrawal; monotherapy; liver dysfunction; drug targeting; neurotoxicity; antineoplastic agent; progression free survival; infection; multiple cycle treatment; anemia; etoposide; blood toxicity; thrombocytopenia; interleukin 21; novel therapies; cyclophosphamide; vincristine; antineoplastic activity; drug resistance; kidney carcinoma; drug dose escalation; pneumonia; rash; b cell lymphoma; cutaneous t cell lymphoma; peripheral t cell lymphoma; t cell lymphoma; acute graft versus host disease; drug mechanism; drug response; graft versus host reaction; sepsis; allogeneic hematopoietic stem cell transplantation; natural killer cell; hydroxychloroquine; immunomodulating agent; anthracycline; leukemia relapse; cytomegalovirus infection; adoptive immunotherapy; alemtuzumab; hematologic disease; belinostat; zidovudine; leukemia remission; human t-lymphotropic virus 1; molecularly targeted therapy; antiproliferative activity; viremia; adult t-cell leukemia/lymphoma; monoclonal antibody dc101; cytokine release syndrome; acute myeloid leukemia; angioimmunoblastic t cell lymphoma; cancer prognosis; combination drug therapy; brentuximab vedotin; glycogen synthase kinase 3 inhibitor; cellular immunotherapy; human; article; cyclophosphamide plus doxorubicin plus etoposide plus prednisolone plus vincristine; immunological antineoplastic agent; chimeric antigen receptor t-cell immunotherapy; mogamulizumab; valemetostat; adult t cell leukemia; human t-cell leukemia/lymphotropic virus type i′; ctx 130; elraglusib; golcadomide; tucidinostat; antilymphocyte therapy |
| Journal Title: | Leukemia Research |
| Volume: | 149 |
| ISSN: | 0145-2126 |
| Publisher: | Elsevier Ltd |
| Date Published: | 2025-02-01 |
| Start Page: | 107642 |
| Language: | English |
| DOI: | 10.1016/j.leukres.2025.107642 |
| PROVIDER: | scopus |
| PUBMED: | 39847921 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PDF -- MSK corresponding author is Steven Horwitz -- Source: Scopus |
